LabMind

ARUP Laboratories

Join Dr. Jon Genzen, professor of pathology with the Spencer Fox Eccles School of Medicine at the University of Utah and chief medical officer at ARUP Laboratories, as he explores the people, ideas, and innovations that shape the clinical lab community.

  1. Oct 14

    An Interview With Dr. Alan Remaley, Dr. Anna Wolska, and Maureen Sampson: Advancing LDL-C Calculation With Modern Equations

    The Friedewald equation has been the standard method for estimating low-density lipoprotein cholesterol (LDL-C) for more than 50 years. However, newer equations can reduce the negative bias that may occur at high triglyceride concentrations or low LDL-C levels, improving the accuracy in cardiovascular disease risk assessment. But if newer calculations are available, why haven't they been adopted more broadly? This episode of LabMind features three scientists from the National Institutes of Health (NIH): Alan Remaley, MD, PhD, FAHA, senior investigator in the Lipoprotein Metabolism Laboratory at the National Heart, Lung, and Blood Institute; Anna Wolska, MS, PhD, FAHA, associate scientist in the Lipoprotein Metabolism Laboratory, and Maureen Sampson, BSMT(ASCP), research clinical laboratory scientist in the Chemistry Service of the Department of Laboratory Medicine at the NIH Clinical Center. They joined us to discuss the evolution of LDL-C estimates and the opportunities associated with implementing newer equations in clinical laboratories. Listen in for an insightful conversation on how advances in lipid testing can improve the assessment of atherosclerotic cardiovascular disease risk. Related Information: DPYD Genotype-Guided Fluoropyrimidine Dosing: FDA and NCCN Updates to Guide 5-FU and Capecitabine Dosing for Oncologists [https://arup.utah.edu/education/nelson-dpyd-2026]William Friedewald on The Friedewald Equation [https://web.archive.org/web/20171121060358/www.epi.umn.edu/cvdepi/essay/william-friedewald-on-the-friedewald-equation/]2026 ACC/AHA Guideline on the Management of Dyslipidemia [https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423]A Modified Sampson-NIH Equation with Improved Accuracy for Estimating Low Levels of Low-Density Lipoprotein-Cholesterol [https://pubmed.ncbi.nlm.nih.gov/40629956/]

  2. Aug 19

    An Interview With Dr. Ryan Nelson: Using Pharmacogenetics To Minimize Toxicity With Chemotherapy

    A single genetic variant can make the difference between effective cancer treatment and life-threatening toxicity. In this episode of LabMind, Ryan Nelson, PharmD, medical director of Precision Medicine at ARUP Laboratories and adjunct professor at the Spencer Fox Eccles School of Medicine at the University of Utah, shares how a growing movement led by patient advocates, researchers, healthcare organizations, and regulators has driven critical updates to guidelines for prescribing fluoropyrimidines, a major class of chemotherapy drugs. Tune in to learn why pharmacogenetic testing is becoming an important tool in cancer care, helping clinicians identify at-risk patients, reduce serious adverse events, and deliver safer, more cost-effective treatments.   Related Information: FDA: Safety Labeling Update: Capecitabine and Fluorouracil (5-FU), Risks Associated With DPD Deficiency. 2026. fda.govFDA: VISTOGARD (uridine triacetate) Prescribing Information. 2015.NCCN: Clinical Practice Guidelines in Oncology: Colon Cancer, v5.2025 (Oct 30, 2025).Nelson R, Shaaban S. DPYD Pretreatment Testing Updates: Guide for Oncologists. ARUP Laboratories, 2026.Deenen MJ, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy. J Clin Oncol. 2016;34(3):227-234. doi:10.1200/JCO.2015.63.1325Henricks LM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy. Lancet Oncol. 2018;19(11):1459-1467. doi:10.1016/S1470-2045(18)30686-7Knikman JE, et al. Survival With DPYD Variant Alleles and Dose-Individualized. Therapy. J Clin Oncol. 2023;41(35):5411-5421. doi:10.1200/JCO.22.02780

About

Join Dr. Jon Genzen, professor of pathology with the Spencer Fox Eccles School of Medicine at the University of Utah and chief medical officer at ARUP Laboratories, as he explores the people, ideas, and innovations that shape the clinical lab community.

You Might Also Like